Search Results
Renewed focus on a national initiative to cure cancer
For more than 66 years The Leukemia & Lymphoma Society (LLS) has dedicated its energy and resources to finding cures for blood cancers, investing more than $1 billion over that time. Last night in his State of the Union address, President Obama appointed Vice President Joe Biden to take the lead in a “moon shot” mission to cure cancer. We at LLS agree the time is right.
“It’s personal for everybody,” the Vice President later said in a statement.
Is a Clinical Trial Right For You?
Because it can take up to 15 years for a new blood cancer drug to be studied and made available for doctors to prescribe, some patients opt for clinical trials as a way to gain early access to a promising treatment. Advancing new cancer therapies requires years of extensive clinical investigation, but clinical trials come with no guarantees. "A drug is allowed to enter the clinical trial phase based on scientific evidence including cell and animal studies, but it's still considered experimental and unproven.
Mechlorethamine
Mechlorethamine is FDA approved to treat people who have Hodgkin lymphoma, chronic myeloid leukemia, chronic lymphocytic leukemia, polycythemia vera and mycosis fungoides.
Teniposide
Teniposide is FDA approved along with other medicines as induction therapy to treat people who have refractory childhood acute lymphoblastic leukemia, non-Hodgkin lymphoma and other types of cancer. This medicine often causes a temporary loss of hair. After treatment with teniposide has ended, normal hair growth should return.
Vinblastine
Vinblastine is an FDA-approved chemotherapy agent that is used to treat people who have acute leukemia. It is sometimes used to treat other types of cancer including lymphoma.
Vorinostat
Vorinostat is FDA approved to treat cutaneous T-cell lymphoma (CTCL) in patients whose CTCL gets worse, does not go away or comes back after treatment with two systemic therapies.
Bendamustine hydrochloride
Bendamustine hydrochloride is FDA approved to treat people who have:
- Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
- Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Denileukin diftitox-cxdl
Denileukin diftitox-cxdl is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
New Study Shows 9/11 Responders Have Higher Rates of Leukemia
All 9/11 responders put their own lives at risk to save others from the events that occurred at the World Trade Center (WTC) on September 11, 2001, in New York City. Since then, several studies have shown elevated rates of cancers such as multiple myeloma, prostate cancer and thyroid cancer among first responders and those who worked nearby.
One More 'Ologist'
After staring down Stage IV non-Hodgkin lymphoma in 2016, I AM HERE, and I am grateful beyond measure. However, I am learning that the treatments that saved my life came at a high cost, and that in its own way survivorship is the hardest part of what I and my family now call, “the adventure.” 'The adventure' is certainly never what we imagined it would be.
CAR T-cell therapy in central nervous system (CNS) lymphoma: a study in safety and efficacy and a model in which to study mechanisms of neurotoxicity
CAR T-cells are highly effective in lymphoma but limited by a profound and potentially fatal toxicity involving the central nervous system (CNS). Little is known about how CAR T-cells eliminate lymphoma cells in the CNS nor how this therapy causes toxicity. I will study CAR T-cells in patients with CNS lymphomas with the goal of expanding CAR T-cell indications. I will also examine serial blood and CNS samples to understand neurologic toxicity to inform new therapies to control this toxicity.Because of You, We're Helping to Cure Cancer
Here at The Leukemia & Lymphoma Society (LLS), we remain laser-focused on continuing to drive forward our mission. In fact, we are amplifying our efforts to help patients and caregivers access the care they need, during the coronavirus crisis and beyond. Thankfully, we have a vibrant community of dedicated volunteers across the country who are just as relentless as we are about making a difference in the lives of blood cancer patients and their families.
Sailing In One Direction to End Childhood Cancer
In the treatment of children with acute myeloid leukemia “We have plateaued. The tools in our toolbox are all sledgehammers.”
This grim assessment was how Dr. E. Anders Kolb, of Nemours/Alfred I DuPont Hospital for Children, characterized the state of treatment for children with this devastating form of leukemia.
Dr. Kolb was among a group of pediatric oncologists to join The Leukemia & Lymphoma Society (LLS) in hosting an event in Atlanta this week to discuss LLS’s new $50 million Children’s Initiative, a multi-faceted effort to:
Support at Your Fingertips: Try a Discussion Board
Having cancer can be a lonely experience, and it’s not always so easy to find others with a similar diagnosis. Even if you could, you might not always want to talk about everything face to face.
Sometimes an online discussion board is just what you need.
On Pride Day, LGBTQI+ Cancer Survivors Share Their Stories
After Spencer graduated from college in 2015, a friend noticed that he had very swollen lymph nodes on his neck.
As he sought medical advice, many healthcare professionals attributed his symptoms to being a side effect of a gender-affirming procedure he had a few months earlier (Spencer is a transgender man). It took several months and numerous appointments before he was diagnosed with stage three Hodgkin lymphoma.
Going to School on Cancer
This blog is the second in a series.
A First-in-human Clinical Trial of CD5 knocked-out Chimeric Antigen T Cells for T-cell Lymphomas
This proposal seeks to develop for the first time in humans a novel CD5 knocked out (KO) anti-CD5 chimeric antigen receptor T cell (CART) product for patients with relapsed or refractory T-cell lymphomas. In Aim#1, we will generate and test a clinical-grade CD5 KO CART5 product, and in Aim#2, we will perform a phase I clinical trial. This project is highly relevant to those parts of the LLS's mission that pertain to the development of personalized and novel therapies for cancer treatment.Methotrexate
Methotrexate is FDA approved, alone or with other drugs, to treat people who have acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to prevent ALL from spreading to the CNS. It is also FDA approved to treat people who have advanced non-Hodgkin lymphoma and advanced mycosis fungoides. It may also be used to treat people with other types of blood cancer.
Doxorubicin
Doxorubicin is FDA approved to treat people who have some kinds of blood cancer, including acute lymphoblastic leukemia, acute myeloblastic leukemia, and Hodgkin and non-Hodgkin lymphoma.
Etoposide
Etoposide is used to treat people who have certain types of blood cancer including Hodgkin and non-Hodgkin lymphoma. It is FDA approved for some types of lung and testicular cancer. This medicine often causes a temporary loss of hair. After treatment with etoposide has ended, normal hair growth should return.